Edition:
India

People: Entera Bio Ltd (ENTX.OQ)

ENTX.OQ on NASDAQ Stock Exchange Capital Market

2.64USD
12:22am IST
Change (% chg)

$0.21 (+8.64%)
Prev Close
$2.43
Open
$2.34
Day's High
$2.64
Day's Low
$2.33
Volume
1,739
Avg. Vol
2,498
52-wk High
$6.29
52-wk Low
$1.60

Ben Ami, David 

Mr. David Ben Ami is Director of the company since 2014. Mr. Ben Ami is the Managing Partner of Corundum Open Innovation Fund, a life sciences venture capital fund, and the Executive Investment Director of SBI JI Innovation Advisory Ltd. Mr. Ben Ami has more than 25 years of experience with activities in management, business development, corporate strategy and investments in the life sciences industry. He served as chief executive officer of NVR Labs Ltd. from 2005 to 2010, Israeli Country Manager of Boston Scientific, Israel from 2003 to 2005, and director of business development of Teva Israel and Teva Medical from 1999 to 2002. In 2008, he founded Macrocure Ltd., and served as the chairman of the board of directors of Macrocure from 2008 until 2016. Mr. Ben Ami currently serves, and in the past served as a board member in numerous companies including: Immunobrain Checkpoint Inc., Novolog Ltd., Degania Medical Ltd., Biocell Ltd., Meytav Technology Incubator, Hairstetics Ltd., VVT Medical and Contipi Medical Ltd. He received his M.B.A. and B.A. in Economics & Management from Tel-Aviv University. Mr. Ben Ami serves on our board of directors as a designee of the Centillion Fund pursuant to rights granted to Centillion Fund under our articles of association as in effect prior to the closing of this offering. For further information regarding our commitment under certain circumstances to nominate one director nominee designated by Centillion Fund following the closing of this offering, see “—?Arrangements for Election of Directors.” Following the consummation of this offering, Mr. Ben Ami intends to resign from our board.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --